NuCana Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Loss Drop 63% YoY

NuCana (NASDAQ: NCNA) reported Q1 2025 financial results and provided updates on its cancer drug pipeline. The company's lead program NUC-7738 has shown promising results in treating PD-1 inhibitor-resistant melanoma, leading to an expansion trial with 28 additional patients. NuCana's second program, NUC-3373, is showing positive data in combination with pembrolizumab for advanced solid tumors. The company reported a reduced net loss of £2.5 million in Q1 2025 compared to £6.8 million in Q1 2024. Following a May financing round raising £8.8 million, NuCana's cash position stands at £4.0 million, with runway extended into Q4 2026. Key upcoming milestones include data readouts from both NUC-7738 and NUC-3373 trials, and regulatory guidance from the FDA for NUC-7738's pivotal study in melanoma.

https://www.stocktitan.net/news/NCNA/nu-cana-reports-first-quarter-2025-financial-results-and-provides-q7lo6cvq2mvt.html